- Home
- KURA
KURA
Kura Oncology Inc.
as 12-18-2024 11:38am EST
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 793.2M | IPO Year: | N/A |
| Target Price: | $30.13 | AVG Volume (30 days): | 2.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.36 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.40 - $24.17 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 106.66% |
Stock Insider Trading Activity of Kura Oncology Inc. (KURA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| FORD KATHLEEN | KURA | Chief Operating Officer | Nov 18 '24 | Sell | $16.03 | 526 | $8,433.73 | 23,184 |
Latest Kura Oncology Inc. News
KURA Breaking Stock News: Dive into KURA Ticker-Specific Updates for Smart Investing
GlobeNewswire
9 days ago
Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting
Insider Monkey
14 days ago
Why Is Kura Oncology, Inc. (KURA) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?
GlobeNewswire
16 days ago
Kura Oncology to Host Virtual Investor Event on December 9, 2024
GlobeNewswire
23 days ago
Kura Oncology to Participate in JMP Securities Hematology and Oncology Summit
Insider Monkey
25 days ago
Kura Oncology, Inc. (KURA): Among the Most Promising Cancer Stocks According to Hedge Funds
BioPharma Dive
a month ago
Halozyme drops Evotec buyout bid; Patient dies in Neurogene trial
Investor's Business Daily
a month ago
Kura Crashes 37% After $1.53 Billion Deal Slams The Door On A Takeover
Investor's Business Daily
a month ago
Kura Oncology Slams The Door On Its Takeover Narrative, And Shares Collapse 26%
Compare KURA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KURA Kura Oncology Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.